Trial Profile
An open-label, parallel-group, bioavailability study to assess the pharmacokinetics of CAT-354 following subcutaneous and intravenous administration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2017
Price :
$35
*
At a glance
- Drugs Tralokinumab (Primary) ; Tralokinumab (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors MedImmune
- 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
- 15 Apr 2008 Dosing has begun according to a MedImmune media release.
- 15 Apr 2008 Status changed from initiated to recruiting according to a MedImmune media release.